New Releases from NCBI BookshelfTofacitinib for moderately to severely active ulcerative colitis.Tofacitinib for moderately to severely active ulcerative colitis.
Post Content
Uncategorized
New Releases from NCBI BookshelfDelgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].Delgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Anzupgo be reimbursed by public drug plans for the treatment of moderate to severe
Uncategorized
New Releases from NCBI BookshelfVanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Alyftrek be reimbursed by public drug plans for the treatment of cystic fibrosis (CF)
Uncategorized
New Releases from NCBI BookshelfInavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].Inavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Itovebi in combination with palbociclib (PAL) and fulvestrant (FUL) be reimbursed by public drug
